ERBB2 and breast carcinoma: 64Cu-Trastuzumab, 64Cu-DOTA-Zher2:477, 68Ga-Trastuzumab (Fab’), 68Ga-ABY-002, and 89Zr-Trastuzumab have all been used for noninvasive detection and evaluation of HER2 expression in breast cancer [193].